Established in 1993 and based in Hackensack, New Jersey, Protalix BioTherapeutics, Inc. is a biopharmaceutical company primarily focused on advancing and globally commercializing recombinant therapeutic proteins. The firm utilizes its proprietary ProCellEx plant cell-based protein expression system to develop these treatments, reaching patients in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and other international regions. Protalix currently offers Elelyso, a treatment for Gaucher disease. Its robust product pipeline includes PRX-102, a therapeutic protein candidate now in late-stage clinical trials for Fabry disease. Also in development are PRX-110, a plant cell-derived recombinant human deoxyribonuclease I, which has successfully completed Phase IIa clinical trials for cystic fibrosis; PRX-115, a recombinant PEGylated Uricase expressed in plant cells for addressing gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate targeting NETs-related diseases. The company maintains strategic alliances and collaborations with key partners such as Pfizer, Fundação Oswaldo Cruz (Fiocruz), and Chiesi Farmaceutici S.p.A.
seekingalpha.comProtalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 13
prnewswire.comProtalix BioTherapeutics Reports First Quarter 2026 Financial and Business Resultsprnewswire.comMay 13
prnewswire.comProtalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026prnewswire.comMay 6
seekingalpha.comProtalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidanceseekingalpha.comMar 24
proactiveinvestors.comAmericans are richer in shares, Europeans in bricks – and that matters nowproactiveinvestors.comMar 19